A randomized phase II study of alternating and sequential regimens of docetaxel and doxorubicin as first-line chemotherapy for metastatic breast cancer.

Abstract

BACKGROUND This phase II study evaluated the feasibility and efficacy of alternating and sequential regimens of docetaxel and doxorubicin as first-line chemotherapy for metastatic breast cancer (MBC). PATIENTS AND METHODS Women with MBC requiring first-line chemotherapy for progressive disease (n = 106) were randomized and received 3-weekly monotherapy… (More)

Topics

Cite this paper

@article{Paridaens2003ARP, title={A randomized phase II study of alternating and sequential regimens of docetaxel and doxorubicin as first-line chemotherapy for metastatic breast cancer.}, author={Robert J. Paridaens and Filip Van Aelst and Vassillis Georgoulias and H Samonnig and Veronique F J Cocquyt and Christoph C. Zielinski and Hubert Hausmaninger and Patricia Willemse and Yvane Boudraa and J. Wildiers and C Ramazeilles and N. Azli}, journal={Annals of oncology : official journal of the European Society for Medical Oncology}, year={2003}, volume={14 3}, pages={433-40} }